Jane Street’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $818K | Buy |
6,207
+1,010
| +19% | +$134K | ﹤0.01% | 6933 |
|
|
2025
Q4 | $737K | Sell |
5,197
-194,023
| -97% | -$28.1M | ﹤0.01% | 6833 |
|
|
2025
Q3 | $28M | Buy |
199,220
+192,138
| +2,713% | +$26M | ﹤0.01% | 1357 |
|
|
2025
Q2 | $890K | Sell |
7,082
-4,660
| -40% | -$534K | ﹤0.01% | 5832 |
|
|
2025
Q1 | $1.3M | Sell |
11,742
-88,028
| -88% | -$11.2M | ﹤0.01% | 5084 |
|
|
2024
Q4 | $13.6M | Buy |
99,770
+75,254
| +307% | +$9.31M | ﹤0.01% | 1608 |
|
|
2024
Q3 | $2.82M | Sell |
24,516
-86,042
| -78% | -$11.8M | ﹤0.01% | 3835 |
|
|
2024
Q2 | $15.2M | Sell |
110,558
-141,446
| -56% | -$19.4M | ﹤0.01% | 1567 |
|
|
2024
Q1 | $34.8M | Buy |
252,004
+238,124
| +1,716% | +$32.5M | 0.01% | 826 |
|
|
2023
Q4 | $1.83M | Sell |
13,880
-73,958
| -84% | -$8.51M | ﹤0.01% | 4484 |
|
|
2023
Q3 | $9.88M | Buy |
87,838
+31,683
| +56% | +$3.34M | ﹤0.01% | 1783 |
|
|
2023
Q2 | $5.3M | Sell |
56,155
-8,577
| -13% | -$838K | ﹤0.01% | 2649 |
|
|
2023
Q1 | $6.55M | Buy |
64,732
+44,617
| +222% | +$4.64M | ﹤0.01% | 2098 |
|
|
2022
Q4 | $2.4M | Sell |
20,115
-110,298
| -85% | -$12.9M | ﹤0.01% | 3576 |
|
|
2022
Q3 | $13.9M | Buy |
130,413
+82,597
| +173% | +$8.38M | 0.01% | 1384 |
|
|
2022
Q2 | $4.66M | Sell |
47,816
-83,943
| -64% | -$7.75M | ﹤0.01% | 2774 |
|
|
2022
Q1 | $12.4M | Sell |
131,759
-49,408
| -27% | -$4.19M | ﹤0.01% | 1726 |
|
|
2021
Q4 | $15.4M | Buy |
181,167
+49,957
| +38% | +$4.6M | 0.01% | 1415 |
|
|
2021
Q3 | $12.6M | Buy |
131,210
+104,441
| +390% | +$9.87M | ﹤0.01% | 1519 |
|
|
2021
Q2 | $2.6M | Sell |
26,769
-31,478
| -54% | -$3.02M | ﹤0.01% | 3820 |
|
|
2021
Q1 | $5.67M | Sell |
58,247
-11,106
| -16% | -$1.16M | ﹤0.01% | 2230 |
|
|
2020
Q4 | $6.65M | Sell |
69,353
-3,786
| -5% | -$366K | ﹤0.01% | 1789 |
|
|
2020
Q3 | $7.03M | Buy |
73,139
+21,446
| +41% | +$2.48M | ﹤0.01% | 1519 |
|
|
2020
Q2 | $6.31M | Buy |
51,693
+42,979
| +493% | +$4.75M | ﹤0.01% | 1589 |
|
|
2020
Q1 | $755K | Buy |
8,714
+2,583
| +42% | +$253K | ﹤0.01% | 3143 |
|
|
2019
Q4 | $659K | Buy |
6,131
+111
| +2% | +$11.6K | ﹤0.01% | 3340 |
|
|
2019
Q3 | $542K | Sell |
6,020
-56
| -0.9% | -$5.23K | ﹤0.01% | 3440 |
|
|
2019
Q2 | $513K | Buy |
6,076
+2,339
| +63% | +$192K | ﹤0.01% | 3549 |
|
|
2019
Q1 | $329K | Sell |
3,737
-2,244
| -38% | -$188K | ﹤0.01% | 4153 |
|
|
2018
Q4 | $427K | Sell |
5,981
-17,552
| -75% | -$1.68M | ﹤0.01% | 3633 |
|
|
2018
Q3 | $2.89M | Buy |
23,533
+20,763
| +750% | +$2.36M | 0.01% | 1526 |
|
|
2018
Q2 | $272K | Sell |
2,770
-16,963
| -86% | -$1.52M | ﹤0.01% | 4230 |
|
|
2018
Q1 | $1.64M | Buy |
19,733
+13,462
| +215% | +$1.14M | ﹤0.01% | 2085 |
|
|
2017
Q4 | $487K | Sell |
6,271
-10,228
| -62% | -$698K | ﹤0.01% | 3215 |
|
|
2017
Q3 | $1.01M | Buy |
16,499
+8,870
| +116% | +$468K | ﹤0.01% | 2294 |
|
|
2017
Q2 | $351K | Buy |
+7,629
| New | +$370K | ﹤0.01% | 3432 |
|
|
2016
Q4 | – | Sell |
-4,892
| Closed | -$221K | – | 4417 |
|
|
2016
Q3 | $248K | Sell |
4,892
-20,802
| -81% | -$1.04M | ﹤0.01% | 3493 |
|
|
2016
Q2 | $1.17M | Buy |
25,694
+9,127
| +55% | +$420K | 0.01% | 1817 |
|
|
2016
Q1 | $655K | Buy |
16,567
+11,351
| +218% | +$450K | ﹤0.01% | 2291 |
|
|
2015
Q4 | $295K | Buy |
+5,216
| New | +$265K | ﹤0.01% | 3122 |
|
|
2015
Q3 | – | Sell |
-9,412
| Closed | -$455K | – | 3961 |
|
|
2015
Q2 | $450K | Sell |
9,412
-3,707
| -28% | -$157K | ﹤0.01% | 2396 |
|
|
2015
Q1 | $521K | Buy |
+13,119
| New | +$469K | ﹤0.01% | 2019 |
|
|
2013
Q4 | – | Sell |
-11,177
| Closed | -$127K | – | 2702 |
|
|
2013
Q3 | $127K | Sell |
11,177
-158,814
| -93% | -$2.18M | ﹤0.01% | 2515 |
|
|
2013
Q2 | $2.27M | Buy |
+169,991
| New | +$2.09M | 0.04% | 403 |
|
Other funds holding NBIX
VPM
VCM
Jane Street's NBIX Position: Q1 2026 in Review
Jane Street increased its Neurocrine Biosciences (NBIX) stake by 19% in Q1 2026, buying an estimated $134K and bringing the position to 6,207 shares worth $818K. The position accounts for ﹤0.01% of the portfolio, ranked #6933.
Jane Street first reported a position in NBIX in Q2 2013 and has held it in 44 quarters since. The position peaked at $34.8M in Q1 2024. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Jane Street held 6,207 shares of Neurocrine Biosciences worth $818K as of Q1 2026.
- Jane Street bought 1,010 Neurocrine Biosciences shares in Q1 2026, an estimated $134K.
- Neurocrine Biosciences made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #6933 holding.
- Jane Street first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 44 quarters since.
- Jane Street's Neurocrine Biosciences position peaked at $34.8M in Q1 2024.
- 695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.